The Valley Desk

ArticleFuture oncology (London, England)Published

Effectiveness of daratumumab plus bortezomib, lenalidomide, and dexamethasone (DVRd) versus VRd for transplant-eligible newly diagnosed multiple myeloma

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Future oncology (London, England)
Published
Subject terms
Humans; Multiple Myeloma; Dexamethasone; Antineoplastic Combined Chemotherapy Protocols; Antibodies, Monoclonal; Treatment Outcome; Retrospective Studies; Adult; Aged; Middle Aged; Female; Male
PubMed ID
42444515
PubMed Central ID
PMC13580475
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal